In the latest twist to IL-6 roller coaster, Roche's Actemra fails PhIII Covid-19 Veklury combo trial

Roche is adding another tally mark to the negative column on Actemra’s mixed record in Covid-19.

The IL-6 drug failed to meet the primary endpoint of REMDACTA, where it was paired with Gilead’s approved antiviral Veklury (remdesivir) for the treatment of patients with severe Covid-19 pneumonia. Adding Actemra didn’t improve time to hospital discharge, the company reported, without breaking down the numbers.